Press Releases

Webcast ImageWebcast
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference (Replay)
08/15/17 at 12:45 p.m. ET
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Tuesday, August 15, 2017 12:45 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/10/17Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
- Audentes plans to initiate Phase 1 / 2 clinical trials for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome in the third quarter of 2017 - Audentes plans to report preliminary clinical data from Phase 1 / 2 studies of AT132 and AT342 by the end of 2017 - In April 2017, strengthened balance sheet with a follow-on financing of $80.6 million in net proceeds SAN FRANCISCO, Aug. 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOL... 
Printer Friendly Version
07/18/17Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
SAN FRANCISCO, July 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe. Dr. Mavilio will be based in Paris. "We are extremely pleased to add Fulvio to the Audentes team," stated Matthew R. Patterson, President and Chief Exe... 
Printer Friendly Version
06/28/17Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, June 28, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its participation in the following upcoming investor conferences: Piper Jaffray GenomeRx Symposium Panel: Gene Therapy – Tackling Manufacturing July 11, 2017, 11:20 am ET The Lotte New York Palace, New York Wedbush PacGrow Health... 
Printer Friendly Version
06/13/17Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
SAN FRANCISCO, June 13, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Jennifer Jarrett to its board of directors. "We are very pleased to welcome Jen to our board of directors," stated Matthew R. Patterson, President and Chief Executive Officer. "Jen is an accomplished life scienc... 
Printer Friendly Version
05/11/17Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
- INDs for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome are active - Strengthened balance sheet with a follow-on financing of $80.7 million in net proceeds - Preliminary clinical data from phase 1 / 2 studies of AT132 and AT342 anticipated in the fourth quarter of 2017 SAN FRANCISCO, May 11, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy pr... 
Printer Friendly Version
05/10/17Audentes Therapeutics to Present At Upcoming Investor Conferences
SAN FRANCISCO, May 10, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference Gene Therapy & Editing Panel May 17, 2017, ... 
Printer Friendly Version
05/08/17Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
SAN FRANCISCO, May 8, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer.  Dr. Gray joined Audentes in 2014 as Vice President, Research and Development, and has successfully built and led teams across the Company's molecula... 
Printer Friendly Version
05/03/17Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, May 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data related to its product candidates AT132 for the treatment of X-linked Myotubular Myopathy, and AT342 for the treatment of Crigler Najjar Syndrome, will be presented at the 20th Annual Meeting of the American Society of Gene... 
Printer Friendly Version
04/18/17Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO, April 18, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $14.50 per share before underwriting discounts and commission. The gross proceeds to Audentes from the offering, before dedu... 
Printer Friendly Version
04/17/17Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it intends to offer and sell 4,750,000 shares of its common stock in an underwritten public offering.  In addition, Audentes intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of common sto... 
Printer Friendly Version
04/17/17Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
SAN FRANCISCO, April 17, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present a corporate overview at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day in Boston, MA.  The presentation is scheduled fo... 
Printer Friendly Version
04/03/17Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
- Preliminary data from ASPIRO, the planned Phase 1 / 2 Clinical Study of AT132, expected in fourth quarter of 2017 SAN FRANCISCO, April 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT... 
Printer Friendly Version
03/20/17Audentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
Data confirm and expand understanding of significant medical burden associated with XLMTM SAN FRANCISCO, March 20, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that data from RECENSUS, a medical chart review of patients with X-linked Myotubular Myopathy (XLMTM), will be presented at the 2017 Muscular Dys... 
Printer Friendly Version
03/09/17Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
- IND for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) submitted - IND for AT342 to treat Crigler-Najjar Syndrome active - Large scale, internal cGMP manufacturing established to support advancement of pipeline programs - Preliminary clinical data from Phase 1 / 2 studies of AT342 and AT132 anticipated in the fourth quarter of 2017 SAN FRANCISCO, March 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and com... 
Printer Friendly Version
03/01/17Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1 / 2 Run-in Study of Patients with Crigler-Najjar Syndrome
- LUSTRO intended to serve as a longitudinal baseline and within-patient control for VALENS, the planned Phase 1 / 2 study of AT342 for the treatment of Crigler-Najjar Syndrome SAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the commencement of LUSTRO, a prospective study desig... 
Printer Friendly Version
02/07/17Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Feb. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners 6th Annual Global Healthcare Conference February 15, 2017, 9:00 am ET Lotte New York Palace... 
Printer Friendly Version
02/01/17Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Preliminary data from VALENS, the Phase 1 / 2 Clinical Study of AT342, expected by end of 2017 SAN FRANCISCO, Feb. 1, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT342, the Company's gen... 
Printer Friendly Version
01/12/17Gene therapy’s big surprise may be in an old South S.F. warehouse
... 
Printer Friendly Version
01/09/17Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
- Filed IND with the FDA for AT342 in Crigler-Najjar Syndrome - Large Scale Internal cGMP Manufacturing Capability Expected to be Established for Entire Pipeline of Four Programs - Preliminary Clinical Data from Lead Programs Expected by Year-End SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseas... 
Printer Friendly Version
01/04/17Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 4, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will provide a corporate overview and 2017 outlook at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  The presentation is scheduled for Tuesday, Januar... 
Printer Friendly Version
12/13/16Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors
SAN FRANCISCO, Dec. 13, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Julie Anne Smith to its board of directors. "We are delighted to welcome Julie to our board of directors," stated Matthew Patterson, President and Chief Executive Officer. "Julie is a seasoned biotech leader with a pro... 
Printer Friendly Version
11/29/16Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
Milestone Establishes Audentes as a Leader in AAV Gene Therapy Manufacturing SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has successfully initiated large-scale cGMP (current Good Manufacturing Practice) production runs in its new, state-of-the-art manufacturing facility. Ma... 
Printer Friendly Version
11/21/16Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference
SAN FRANCISCO, Nov. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its plans to attend the Piper Jaffray 28th Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY on November 29-30, 2016.  Matthew R. Patterson, President and Chief Executive Officer, will participate on a ... 
Printer Friendly Version
11/10/16Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility, Commenced Enrollment in the INCEPTUS Clinical Assessment Study of XLMTM SAN FRANCISCO, Nov. 10, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financi... 
Printer Friendly Version
09/21/16Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 21, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences: LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28, 2016, 9:30 AM ET Lot... 
Printer Friendly Version
08/31/16Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Achievements Included Completion of IPO, Initiation of Large Scale Manufacturing Runs and Enrollment of First Patient in a Clinical Assessment Study of XLMTM SAN FRANCISCO, Aug. 31, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended June 30, 2016 and provided an... 
Printer Friendly Version
08/17/16Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM
Study intended to serve as longitudinal baseline and within-patient control for ASPIRO, the planned Phase 1 / 2 study of AT132 for the treatment of XLMTM SAN FRANCISCO, Aug. 17, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported that the first patient has been enrolled in INCEPTUS, a prospective ... 
Printer Friendly Version
08/08/16Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO, Calif., Aug. 8, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 10:20 am ET. To access the live webcast of the Audentes presentation, p... 
Printer Friendly Version
07/19/16Audentes Therapeutics Announces Pricing of Initial Public Offering
SAN FRANCISCO, July 19, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Audentes. The shares are expected to begin trading on The NASDAQ Global Mark... 
Printer Friendly Version
05/04/16Audentes Therapeutics and the University of Pennsylvania Announce Collaboration to Develop AAV Gene Therapy for Severe Liver Disease
IND filing for AT342 for the Treatment of Crigler-Najjar Syndrome Expected in 2016 and Preliminary Data from a Phase 1/2 Clinical Trial Expected in 2017SAN FRANCISCO, CA – May 4, 2016 – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases, today announced a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Penn... 
Printer Friendly Version
04/27/16Audentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
SAN FRANCISCO, CA – April 27, 2016 – Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients with serious, rare diseases, announced today that data related to its product candidate AT132 will be presented at the 19th Annual Meeting of the American Society of Gene and Cell Therapy to be held in Washington, D.C. on May 4-7th, 2016. The promising results from a long-term pre-clinical study of AT132 in a dog model of X-li... 
Printer Friendly Version
01/05/16Audentes Therapeutics Appoints Scott W. Morrison to Board of Directors
SAN FRANCISCO, CA – January 5, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Scott Morrison to its board of directors. Mr. Morrison will serve as chairman of the Audentes Therapeutics audit committee.“We are excited to have Scott join the Audentes team,” stated Matthew Patterson, President and Chief Executive Officer. “Scott b... 
Printer Friendly Version
10/13/15Audentes Therapeutics Raises $65 Million In Series C Financing
Leading Healthcare Investors Provide Funding to Advance AAV Gene Therapy Pipeline in Serious, Rare Diseases to Key Clinical Milestones and to Build Internal Manufacturing CapabilitiesSAN FRANCISCO, CA – October 13, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the closing of an oversubscribed $65 million Series C financing. The financing was co-led b... 
Printer Friendly Version
09/29/15Audentes Therapeutics Expands Senior Leadership Team
Natalie Holles Appointed Chief Operating Officer, Thomas Soloway Appointed Chief Financial Officer and Kevin Baker, Ph.D. Appointed Senior Vice President, Preclinical DevelopmentSAN FRANCISCO, CA – September 29, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the addition of three accomplished biopharmaceutical executives to its leadership team. Natali... 
Printer Friendly Version
09/01/15Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences
Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an Inherited Arrhythmia with a High Risk of MortalitySAN FRANCISCO, CA – September 1, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the acquisition of Cardiogen Sciences, Inc., a biotechnology company focused on the discovery and developmen... 
Printer Friendly Version
08/26/15Audentes Therapeutics Receives Orphan Drug Designation for AT001 for the Treatment of X-Linked Myotubular Myopathy in the US and Europe
SAN FRANCISCO, CA – August 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that AT001, an investigational product in development for the treatment of X-Linked Myotubular Myopathy (XLMTM), has been granted orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).XLMTM is a rare, severe, inherited disord... 
Printer Friendly Version
05/14/15Audentes Therapeutics To Participate In 2015 Piper Jaffray Genomerx Symposium & 1×1 Day
SAN FRANCISCO, CA – May 14, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, and John T. Gray, PhD, Vice President, Research and Development, will participate in the 2015 Piper Jaffray GenomeRx Symposium & 1×1 Day at The New York Palace Hotel in New York City on May 20-21, 2015.About ... 
Printer Friendly Version
05/11/15Audentes Therapeutics Announces New Data To Be Presented At American Society Of Gene And Cell Therapy Annual Meeting
Compelling additional preclinical data further support therapeutic potential of gene therapy products to treat X-Linked Myotubular Myopathy and Pompe DiseaseSAN FRANCISCO, CA – May 11, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that new data from its lead development programs will be presented at the 18th Annual Meeting of the American Society of ... 
Printer Friendly Version
04/21/15Audentes Therapeutics Appoints Stephen Squinto, Ph.d. To Its Board Of Directors
SAN FRANCISCO, CA – April 21, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Stephen Squinto, Ph.D., to the company’s Board of Directors. Dr. Squinto, a co-founder of Alexion Pharmaceuticals, Inc., will serve as an independent director to Audentes.“Steve is a pioneer in bringing innovative therapies to patients with rare diseases. A... 
Printer Friendly Version
02/26/15Audentes Therapeutics Joins Global Organizations In Celebrating Rare Disease Day® 2015
New Audentes Patient Advocacy Website Created to Serve Patient CommunitySAN FRANCISCO, CA – February 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced its support for Rare Disease Day®, to be held on February 28th, 2015.  The theme of this year’s Rare Disease Day is Living with a Rare Disease.  In honor of the day, Audentes is pleased to an... 
Printer Friendly Version
12/02/14Audentes Therapeutics Raises $42.5 Million In Series B Financing
Deerfield, Sofinnova, and Venrock Join Existing Investors to Propel Leading Gene Therapy Company Through Significant Clinical and Corporate Development MilestonesSAN FRANCISCO, CA – December 2, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the closing of a $42.5 million Series B financing. Deerfield Management led the financing with participation fro... 
Printer Friendly Version
11/20/14Audentes Therapeutics To Present At The Piper Jaffray Healthcare Conference
SAN FRANCISCO, CA – November 20, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will present a corporate overview at the 26th Annual Piper Jaffray Healthcare Conference in New York City on Tuesday, December 2, 2014 at 12:30pm Eastern.About Audentes Therapeutics, Inc.Audentes is a biotechno... 
Printer Friendly Version
10/01/14Audentes Therapeutics Announces Continued Expansion Of Senior Management Team
John T. Gray, Ph.D., Brings Leading Gene Therapy Research and Manufacturing Expertise to CompanySAN FRANCISCO, CA – October 1, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, has announced the continued expansion of its leadership team, including the appointment of John T. Gray, PhD., as Vice President, Research and Development.  Dr. Gray brings more than 20 year... 
Printer Friendly Version
09/24/14Audentes Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
SAN FRANCISCO, CA – September 24, 2014 – Audentes Therapeutics, Inc., a private biotechnology company dedicated to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York City on October 1, 2014.About Audentes Therapeutics, Inc.Audentes is a biotechnology company committed to t... 
Printer Friendly Version
05/19/14Audentes Therapeutics Announces Six Abstracts To Be Presented At The American Society Of Gene And Cell Therapy Meeting May 21-24, 2014
Data to be presented demonstrate continued encouraging results from preclinical studies of AT001 for the treatment of X-Linked Myotubular MyopathySAN FRANCISCO – May 19, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the presentation of results from ongoing preclinical studies of AT001 (AAV-MTM1), Audentes’ novel therapeutic in development for th... 
Printer Friendly Version
03/04/14Audentes Therapeutics Announces Significant Additions To Leadership Team
Dr. Suyash Prasad joins as Senior Vice President and Chief Medical OfficerSAN FRANCISCO, CA – March 4, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development and commercialization of innovative treatments for rare diseases using gene therapy technology, has announced the expansion of its leadership team, including the appointment of Suyash Prasad, M.D. as Senior Vice President and Chief Medical Officer.  Dr. Prasad is the latest addition to a managemen... 
Printer Friendly Version
02/05/14Audentes Therapeutics And Genethon Announce Agreement To Develop Treatment For Severe Genetic Disease X-linked Myotubular Myopathy
Promising preclinical data recently published in Science Translational MedicineSAN FRANCISCO, CA – February 5, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non-profit organization dedicated to the research and development of biotherapies for orphan genetic diseases, announce that they have entered into an agreement to develop AT001 for the treatment of X-Linked Myotubular Myopathy (XLMT... 
Printer Friendly Version
07/30/13REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS
WASHINGTON & SAN FRANCISCO – July 30, 2013 – REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease using NAV vectors.Under the terms of the Agreement, REGENX granted Audentes an exclusive worldwide license, with rights to sublicense, to REGENX’s NAV rAAV8 and rAAV9 vectors for treatment of XLMTM and Pompe... 
Printer Friendly Version
07/18/13AUDENTES THERAPEUTICS RAISES $30 MILLION IN SERIES A FINANCING
Funding creates premier global biotechnology company dedicated to the development of treatments for rare muscle diseases using gene therapy technologySAN FRANCISCO, CA. – July 18, 2013 – Audentes Therapeutics Inc., a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, today announced the closing of a $30 million Series A financing. The financing was led by OrbiMed Advisors with the participation of 5AM Ventures and Versant V... 
Printer Friendly Version